Decitabine and Cedazuridine (ASTX727)
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Function
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 18 patients (estimated)
- Sponsors
- Taiho Oncology, Inc.
- Tags
- Cytidine Deaminase Inhibitor (CDAi), DNMT1 Inhibitor, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2135
- NCT Identifier
- NCT04953897
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.